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Biomarkers and subtypes of breast cancer
Breast cancer is not a single disease. Clinically, breast cancer 
has been known to have distinct prognosis and response 
to chemotherapies based on the immunohistochemical 
(IHC) subtypes [e.g., estrogen receptor (ER), progesterone 
receptor (PgR), and human epidermal growth factor 
receptor 2 (HER2)] (1,2). hormone receptor (HR)-positive 
(ER and/or PgR-positive)/HER2-negative breast cancers 
have a good response to hormone therapy and favourable 
prognosis. HER2-positive and triple-negative (TN: ER, 
PgR and HER2-negative) breast cancers have poor baseline 
prognosis, and good response to HER2 targeted therapy 
and chemotherapy, respectively. In 2000, molecular subtypes 
(luminal A, luminal B, HER2 enriched, and basal) in breast 
cancer were reported (3). mRNA expression patterns in a 
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set of 65 surgical samples of human breast cancers provided 
a distinctive molecular subtype of each cancer (3). Tumor 
grade divides HR-positive/HER2-negative tumors into 
luminal A and B. This discrimination serves to determine 
the indication of chemotherapy. Gene expression patterns 
in HR-positive/HER2-negative tumors have been used 
to improve the genomic markers that may have better 
predictive power over classical pathological biomarkers (4). 
On the other hand, an additional clinical value in HER2-
positive or TN subtypes is small due to close resemblance 
to IHC ER, PgR and HER2. Many of these breast cancer 
subtypes represent biologically distinct disease entities, 
indicating that each subtype has a distinct prognosis and 
response to chemotherapy (1,2). These observations lead 
to the theory that each subtype should have a distinct 
biomarker (5). Almost twenty years have elapsed since the 
molecular subtypes were established by Dr. Perou (3); but, 
how many additional next-generation biomarkers after IHC 
ER, PgR and HER2 have been available in routine clinical 
use for early-stage breast cancers in the adjuvant setting? 
It takes a long time to introduce a biomarker into daily 
clinic, due to the lack of consistent evidence, inadequate 
validation of the biomarker, inadequate evidence of clinical 
significance, operational barriers to clinical implementation, 
and inadequate evidence of operational effectiveness or 
impact in clinical care (6). A biomarker refers to a measurable 
variable that is associated with the cancer outcome. There 
is a giant confusion regarding the distinction between a 
predictive and a prognostic biomarker (7). A prognostic 
biomarker informs about a likely cancer outcome (e.g., 
cancer recurrence, cancer progression, and death) impartial 
of treatment received. If a biomarker is prognostic and 
therapy is efficacious, the therapeutic benefit is similar for 
both biomarker-positive and biomarker-negative patients; 
though the biomarker will nonetheless be associated with a 
differential outcome, depending on whether it is present or 
absent. On the other hand, a biomarker is predictive if the 
therapeutic effect is unique for biomarker-positive patients 
compared to biomarker-negative patients. In this review, we 
describe biomarkers of neoadjuvant/adjuvant chemotherapy 
for breast cancer taking prognostic and predictive response 
to chemotherapy into consideration. 
First-generation genomic signatures
Several first-generation genomic signatures highly 
associated with cell cycle and proliferation have been 
described for HR-positive/HER2-negative and node-
negative breast cancer. Two of these (the 21-gene 
recurrence score: Oncotype DX, Genomic Health and 
the 70-gene signature: MammaPrint, Agendia Inc.) were 
tested by prospective randomized and controlled trials to 
assess their ability to predict prognosis and chemotherapy 
response. They are now increasingly used in clinical 
practice. An encouraging finding is that first-generation 
genomic signatures showed similar overall performance 
despite the limited overlap of genes (8). Several common 
features of TN and HER2-positive tumors had excessive 
expression of tumor-differentiation genes, together with 
numerous cell-cycle and proliferation genes (9). In contrast, 
the HR-positive combined luminal A and luminal B 
subtypes were not homogeneous (3). Since HR status and 
histologic grade are predictors of prognosis and response to 
chemotherapy or even endocrine therapy, and those features 
are associated with large scale gene expression differences, 
the first-generation genomic signatures invariably included 
many genes that capture the clinical phenotype (i.e., HR 
status and histologic grade) (10). Another critical and 
consistent finding in the field of genomic prognostic 
markers is the tumor size and nodal status. Although these 
have strong prognostic power, they have no powerful gene 
signatures inherently associated with them. In almost all 
research, these anatomical pathological variables continue 
to be statistically significant and independent predictors 
of prognosis (9,11,12). However, neither tumor size nor 
nodal status has a strong and consistent association with 
therapeutic sensitivity (i.e., probability and quantity of 
response to therapy).
The 70-gene signature has been developed using cDNA 
microarray analysis on primary breast cancer samples 
of 117 patients, which applied supervised classification 
to identify a gene expression signature predictive of 
breast cancer prognosis (13). The phase 3 randomized 
MINDACT (Microarray in Node-Negative and 1 to 3 
Positive Lymph Node Disease May Avoid Chemotherapy) 
study, including 6,693 patients with early-stage breast 
cancer, aimed to provide prospective evidence of the clinical 
benefits of adding the 70-gene signature to classical clinical-
pathological variables in choosing patients for adjuvant 
chemotherapy. It showed that approximately 46% of breast 
cancer patients with high clinical risk might not need 
chemotherapy (14). Based on the results of the MINDACT 
study, ASCO guidelines were updated, stating that the 70-
gene signature can be used for patients at high clinical risk 
to decide whether to withhold adjuvant chemotherapy. This 
method can help identify a good-prognosis population, 
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who would get limited benefit from chemotherapy, among 
HR-positive/HER2-negative and lymph node-negative 
patients (15). On the other hand, for patients in the low 
clinical risk category, the 70-gene signature does not 
have clinical benefits because they did not benefit from 
chemotherapy, irrespective of the risk group. 
Another genomic assay, the 21-gene recurrence score, 
exemplifies the candidate-gene approach to predict the 
outcome. It measures the expression of ER and HER2, 
as well as that of ER-regulated transcripts and several 
proliferation-related genes, by quantitative reverse 
transcriptase-polymerase chain reaction (qRT-PCR) (11). 
The 21-gene recurrence score measures these variables 
into a recurrence score, which can be used as a continuous 
variable to predict the probability of recurrence in ten years 
and to group patients into low, intermediate, and high risk 
groups (11). Patients who had HR-positive/HER2-negative 
and lymph node-negative breast cancer with a recurrence 
score of 11–25 were randomized to receive hormone 
therapy alone or in combination with chemotherapy (16). 
For a recurrence score of <11, patients received hormone 
therapy, and for a recurrence score of >25, patients received 
a combination therapy. For a patient with a recurrence 
score of <11, the 5-year disease-free survival (DFS) was 
93.8% [95% confidence interval (CI), 92.4 to 94.9] and the 
overall survival (OS) was 98.0% (95% CI, 97.1 to 98.6) (17), 
indicating clinicians may offer hormone therapy alone. For 
the patients with intermediate-risk, recurrence score of 11 
to 25 had a similar efficacy between adjuvant endocrine 
therapy and chemo-endocrine therapy (18). For the patients 
with a high score of 26 to 100, who received adjuvant 
chemotherapy, the estimated 5-year DFS was 93% better 
than that expected with endocrine therapy alone (19). 
Based on this evidence, NCCN guidelines Version 3.2019 
recommends using 21-gene recurrence score for NCCN 
category “1” disease as a prognostic and a predictive 
marker (20). There is no other method that is recommended 
both as a prognostic and a predictive marker in these 
guidelines (20). If a patient has HER2-positive or TN 
breast cancer, the physicians should not use the 21-gene 
recurrence score to make decisions on adjuvant systemic 
therapy (21). 
The role of the first-generation signature for HR-
positive/HER2-negative and node-positive breast cancer 
is another challenging area. Nodal status in breast cancer 
is a prognostic but not a predictive marker (9). Typically, 
patients with HR-positive and node-positive breast cancer 
should be prescribed not only hormone therapy but 
also chemotherapy, because they have a poor prognosis 
regardless of the sensitivity to chemotherapy. Albain et al. 
reported that the 21-gene recurrence score is prognostic 
for hormone-treated node-positive patients and predicted a 
significant benefit of chemotherapy with cyclophosphamide, 
doxorubicin, and fluorouracil in breast cancers with a 
high recurrence score in the retrospective data set of 367 
patients with breast cancer (22). Stemmer et al. showed 
the 5-year DFS of patients treated with N1 (1–3 positive 
lymph nodes) with a recurrence score <18, who received 
hormone therapy alone, to be 2.7% (95% CI, 1.4–5.1%) 
in the retrospective analysis of a prospectively designed 
study (23). The prospective phase 3 PlanB trial showed that 
the 21-gene recurrence score is prognostic for hormone-
treated node-positive patients and their 5-year DFS with a 
recurrence score ≤11 is 94.4% (95% CI, 89.5–99.3%) (24). 
A phase 3, randomized clinical trial, RxPONDER, to 
assess the significance of chemotherapy for patients with 
N1 and recurrence score ≤25 is in progress (ClinicalTrials.
gov Identifier: NCT01272037). This trial should provide 
evidence if the 21-gene recurrence score can predict the 
efficacy of chemotherapy for patients with N1 and HR-
positive/HER2-negative breast cancers. NCCN guidelines 
v3.2019 states that multigene assays are prognostic, but not 
predictive, for patients with pN1. We are looking ahead to 
the consequences of phase 3 RxPONDER trial. 
In summary, prospective randomized controlled trials for 
first-generation signatures, especially the 70-gene signature 
and the 21-gene recurrence score have been conducted and 
had met the primary endpoint that HR-positive/HER2-
negative and node-negative patients with intermediate-
risk can safely skip unnecessary chemotherapy. The node-
positive setting is being tested for its predictive value for the 
multigene assay in a prospective randomized phase 3 trial. 
These assays will be more frequently used in the future.
Residual disease after neoadjuvant 
chemotherapy
Neoadjuvant chemotherapy is the standard therapy for 
locally advanced breast cancers and an alternative option 
for primary operable breast cancers. Neoadjuvant and 
adjuvant chemotherapy should clinically have a similar 
effect on the clinical outcomes, including DFS and OS (25). 
In one particular trial, there was no significant difference in 
DFS and OS (P value =0.99 and 0.83, respectively) among 
patients in the neoadjuvant and adjuvant chemotherapy-
treated groups. Most patients were treated pre-operatively 
Iwamoto et al. Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer
© Chinese Clinical Oncology. All rights reserved.   Chin Clin Oncol 2020;9(3):27 | http://dx.doi.org/10.21037/cco.2020.01.06
Page 4 of 7
before undergoing lumpectomy and radiation therapy post-
operatively (67.8% versus 59.8%, respectively) (25). One 
purpose of the neoadjuvant chemotherapy is to be able 
to perform lumpectomy for cosmetic reasons and to have 
better clinical outcomes like a total mastectomy. Another 
purpose is to get clinical information on the response to 
therapies and provide additional therapies to improve 
clinical outcomes. Pathological complete response (pCR) 
after neoadjuvant chemotherapy is associated with long-
term survival and has been adopted as the primary endpoint 
for neoadjuvant trials (25,26). Cortazar et al. reported the 
predictive value for survival by pCR after neoadjuvant 
chemotherapy (27). The prognostic value is the greatest 
in HER2-positive and TN subtypes (27), indicating that 
neoadjuvant chemotherapy provides an chance to observe 
the efficacy of a selected chemotherapy regimen directly. 
Patients with residual breast cancer after neoadjuvant 
chemotherapy are at a high-risk of recurrence of metastases, 
which make these patients ideal applicants for clinical trials. 
Two clinical trials, CREATE-X (28) and KATHERINE (29), 
have shown improved breast cancer outcomes with post-
operative capecitabine and ado-trastuzumab emtansine 
treatment for patients who had either TN or HER2-
positive breast cancer, respectively, who had residual 
cancer after neoadjuvant chemotherapy. Administering the 
additional agent for HER2-positive or TN patients with 
residual disease after neoadjuvant treatments may be a new 
framework to maximize a chance of survival (30).
In HR-positive/HER2-negative cancers, the clinical 
significance of pCR after neoadjuvant chemotherapy is 
not verified. Pooled analysis showed pCR was positively 
associated with event-free survival (HR 0.49, 95% CI, 0.33–
0.71) and OS (0.43, 0.23–0.71), weaker than HER2-positive 
and TN breast cancers (27). As the adjuvant treatment, 
hormone therapies are prescribed to the majority of HR-
positive patients. The correlation between pCR and survival 
is more complicated in HER2-positive and TN patients, 
because of the influence on hormone therapy, as showing in 
the following “Tumor-infiltrating lymphocytes” section.
Residual cancer burden (RCB) score that is measured 
as a continuous value combining pathologic measurements 
of the primary tumor (cellularity and size) and metastatic 
lymph node (size and number) may be a more powerful 
predictor than residual  cancer after  neoadjuvant 
chemotherapy (31). RCB can be prognostic for long-term 
survival after neoadjuvant chemotherapy not only in HER2-
positive and TN breast cancers but also in the HR-positive/
HER2-negative subtype (32). 
Tumor-infiltrating lymphocytes (TILs)
There are no diagnostic multigene assays for HER2-
positive and TN breast cancers. There is only classical 
clinical and pathological information (tumor size, nodal 
or distant metastatic status) for the decision making in the 
adjuvant setting in daily clinic. The extent of TILs by the 
assessment of hematoxylin and eosin (H&E)-stained tumor 
specimens is known to provide prognostic data, particularly 
in HER2-positive and TN breast cancers (33-35), but not 
in the HR-positive subtype, in the adjuvant setting. Loi 
et al. reported that a 10% increase in the stromal TILs 
is associated with a 15% reduced risk of recurrence (P 
value =0.025) and a 17% reduced risk of death in ER-
negative/HER2-negative breast cancers, irrespective of 
the chemotherapy regimen (33). Similarly, 10% increased 
stromal TILs is associated with a 14% reduced risk of 
relapse or death (P value =0.02), an 18% reduced risk of 
distant relapse (P value =0.04), and a 19% of death (P value 
=0.01) in patients with TN breast cancer (34). In HER2-
positive breast cancers, each 10% increase in TILs was 
significantly decreased recurrence in patients who received 
trastuzumab containing regimen (35). Furthermore, 
core needle biopsies from more than 3,000 breast cancer 
patients, before the treatment, have been evaluated to 
understand the predictive value of immune markers as a 
response to neoadjuvant chemotherapy (36). In a pooled 
analysis, the presence of higher TILs in pre-treated tumors 
was associated with favourable pCR rate to neoadjuvant 
chemotherapy (OR 3.93, 95% CI, 3.26–4.73) (36). 
The more, TILs expected higher pCR rates in TN (OR 
2.49, 95% CI, 1.61–3.83) and HER2-positive (OR 5.05, 
95% CI, 2.86–8.92), not in HR-positive (OR 6.21, 95% 
CI, 0.86–45.15) breast cancers (36). Similar analyses have 
reported that the higher levels of stromal TILs expected 
pCR (P value <0.001) in HER2-positive and TN breast 
cancers (37). Trastuzumab and pertuzumab containing 
regimen in HER2-positive breast cancers were also 
evaluated, where the high TIL levels in pre-treated tumors 
were significantly predictive of pCR in HER2-positive 
breast cancer (38). In summary, increased TILs can be a 
predictor of both response to chemotherapy and prognosis 
after chemotherapy for patients with HER2-positive and 
TN breast cancers, but not HR-positive breast cancers. 
Association between immune functions and HR-
positive breast cancer is another interesting topic. Although 
chemotherapy may be prescribed based on the clinical, 
pathological, and genomic risk, hormone therapy may 
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be given to the majority of the patients with HR-positive 
invasive breast cancer, regardless of the clinical and 
pathological risk. Even if patients with HR-positive breast 
cancer achieve pCR after neoadjuvant chemotherapy, 
indicating they have a good response to chemotherapy, 
pCR cannot be an indicator of favorable prognosis after 
surgery. Prediction of prognosis in HR-positive breast 
cancers treated with hormone therapy should take into 
consideration the response not only to chemotherapy but 
also to hormone therapies. Dunbier et al. showed that a 
higher expression of immune-associated genes such as 
SLAMF8 and TNF as well as TILs is associated with a poor 
response to hormone therapies (P value <0.001) (39). 
So far, we know that TILs cannot be used to either 
withhold or provide chemotherapy in the TN subtype 
or trastuzumab therapy in the HER2-positive subtype, 
because of the absence of standardized guidelines and 
limited evidence concerning reproducibility and clinical 
validity (40). A group of experts for TILs evaluation 
(the International TIL Working Group), reported 
recommendations to improve the consistency of TILs 
scoring and detailed suggestions for annotating TILs (41); 
however, it is not widely used in daily clinic. Kochi et al. 
reported the genomic signature related to TILs could 
be prognostic and potentially predictive as a response to 
chemotherapy in some breast cancer subtypes to overcome 
the low reproducibility of evaluations of TILs (42). The 
measurement of TILs by digital image analysis and machine 
learning algorithms with artificial intelligence might be 
useful for standardization of assessment for TILs in the 
future.
Conclusions
The improvement of tumor biomarkers ready for clinical 
use is a long process. A good biomarker should be a 
predictor of not only prognosis but also the response to 
therapies. Any new scientific intervention can be adopted 
into clinical practice only in the putting of level 1 evidence, 
and though costly, such evidence is provided in a prospective 
randomized clinical trial. Majority of the evidence to 
change the guidelines have come from the prospective 
randomized phase 3 trials. Simon et al. advocated that 
“prospective-retrospective” designs and archived samples 
from datasets with high-quality might be more efficient (43). 
In the future, clinical trials with a more efficient design are 
needed.
For HR-positive/HER2-negative subtype, only two 
biomarkers, the 21-gene recurrence score and the 70-gene 
signature, have been tested in prospective randomized 
clinical trials (14,17,18). There are no diagnostic multigene 
assays for HER2-positive and TN breast cancers. TILs 
have been assessed to have a predictive value for prognosis 
and response to chemotherapy from the retrospective 
analyses. So far, TILs cannot be used to either withhold or 
provide chemotherapy based on the absence of standardized 
evaluation guidelines and confirmed information for 
HER2-positive and TN breast cancers. To overcome the 
low reproducibility of evaluations of TILs, gene signatures 
or digital image analysis and machine learning algorithms 
with artificial intelligence may be useful for standardization 
of assessment for TILs in the future.
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